Trump Drug Pricing Win Overstated: States Still Wary — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump administration officials claimed at a White House event last Friday that every U.S. state had agreed to participate in the GENEROUS model, a federal initiative designed to lower drug prices for state Medicaid programs.
- Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, said at the event: "It's such a good deal that every state realized they need to take it."
- Several state officials told STAT they are actually still undecided on whether to participate, even though they technically applied to the program.
- Other states are still weighing whether the GENEROUS model offers a better deal than the rebates they currently negotiate directly with drugmakers.
Why it matters: The gap between the White House's 'every state is on board' framing and states that remain undecided means the GENEROUS model lacks the universal participation officials described. State Medicaid programs cover tens of millions of low-income patients, and selective or delayed adoption would blunt the initiative's promised savings before it gets off the ground.
Ask SkimNews
